SA
Therapeutic Areas
Eloxx Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ELX‑02 | Cystic Fibrosis (nonsense mutations) | Phase 1 |
| ZKN013 | Familial Adenomatous Polyposis (APC mutation) | Preclinical |
| RMA (cMYc targeting) | MYC‑amplified cancers | Preclinical |
| Drug | Indication | Phase |
|---|---|---|
| ELX‑02 | Cystic Fibrosis (nonsense mutations) | Phase 1 |
| ZKN013 | Familial Adenomatous Polyposis (APC mutation) | Preclinical |
| RMA (cMYc targeting) | MYC‑amplified cancers | Preclinical |